Spring Bank Pharmaceuticals (SBPH) Getting Somewhat Positive Media Coverage, Report Shows
News articles about Spring Bank Pharmaceuticals (NASDAQ:SBPH) have been trending somewhat positive on Monday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Spring Bank Pharmaceuticals earned a news impact score of 0.12 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.5473096031401 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Shares of Spring Bank Pharmaceuticals (NASDAQ SBPH) traded up $0.53 during mid-day trading on Monday, hitting $18.72. The stock had a trading volume of 22,700 shares, compared to its average volume of 43,641. Spring Bank Pharmaceuticals has a fifty-two week low of $6.31 and a fifty-two week high of $18.89.
Several research firms have weighed in on SBPH. Chardan Capital reiterated a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Monday, November 6th. B. Riley began coverage on Spring Bank Pharmaceuticals in a research note on Monday, November 6th. They set a “buy” rating and a $30.00 price target on the stock. ValuEngine downgraded Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. Dawson James reiterated a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Monday, August 7th. Finally, Cantor Fitzgerald began coverage on Spring Bank Pharmaceuticals in a research note on Wednesday, July 19th. They set an “overweight” rating and a $29.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. Spring Bank Pharmaceuticals currently has an average rating of “Buy” and an average price target of $27.25.
COPYRIGHT VIOLATION NOTICE: “Spring Bank Pharmaceuticals (SBPH) Getting Somewhat Positive Media Coverage, Report Shows” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/11/13/spring-bank-pharmaceuticals-sbph-getting-somewhat-positive-media-coverage-report-shows.html.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.
Receive News & Ratings for Spring Bank Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.